ClinicalTrials.gg
RecruitingNCT06582875Updated May 6, 2025

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

A Phase 2 interventional study of Tirzepatide and Placebo in Autosomal Dominant Polycystic Kidney and Obesity, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by University of Colorado, Denver · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver — 1 open to participants now, 5 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · University of Colorado, Denver.

Planned enrollment
2nd of 11
126 · median 61
Started
2025
the only one that year
Phase 2
3 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 12th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

1 of the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, or all of them as a file.
02

Study summary

The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.

Read the detailed description

Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to kidney failure. The only approved treatment to decelerate kidney disease progression in patients with ADPKD is tolvaptan, but its usage is limited due to frequent side effects affecting adherence. Thus, alternative interventions that may slow ADPKD progression hold considerable clinical importance. In line with the general population, body-mass index and insulin resistance have been increasing in patients with ADPKD. The investigators have shown that visceral adiposity associates strongly with accelerated progression of early-stage ADPKD. Pilot study suggested that diet-induced weight loss may slow kidney growth (% in height-adjusted total kidney volume [htTKV] by magnetic resonance imaging), and the study team is currently evaluating the efficacy of daily caloric restriction-induced weight loss for slowing ADPKD progression in a phase IIa clinical trial. However, the long-term adherence to lifestyle interventions is challenging, making pharmacological interventions a compelling adjunct or alternative. Moreover, the study team recently demonstrated that adults with ADPKD and preserved kidney function exhibited insulin resistance (via the gold-standard hyperinsulinemic-euglycemic clamps) and impaired kidney oxidative metabolism (via 11C-acetate PET), which were strongly associated with htTKV. These novel data suggest that targeting improvements in insulin sensitivity and kidney oxidative metabolism, in addition to weight loss, may slow ADPKD progression. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) were recently FDA-approved for the treatment of obesity and show promise in substantially reducing adiposity and improving insulin sensitivity. Additionally, evidence indicates that GLP-1RAs may transform CKD management by reducing kidney events in patients with and without diabetes, via effects extending beyond glycemic modulation, and in part via attenuated kidney inflammation and oxidative stress. However, GLP-1RAs have not yet been evaluated as a novel therapy for slowing ADPKD progression in patients with overweight/obesity. Thus, the current study is a 12-month, phase II, randomized, placebo-controlled, double-blind clinical trial using a GLP-1RA in 126 adults with ADPKD and overweight or obesity to slow kidney growth (primary outcome). The trial will also evaluate changes in total body weight, adipose volume and function, insulin resistance, kidney oxidative metabolism, and inflammation, and carefully monitor safety and tolerability. As a novel therapeutic in ADPKD, GLP-1RAs could transform the treatment landscape for patients.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney
  • Obesity

Keywords

  • GLP1RA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age
  • ADPKD diagnosis based on the modified Pei-Ravine criteria
  • Body-mass index of ≥27 kg/m\^2
  • Estimated ≥ 30 mL/min/1.73m\^2
  • Mayo Classification of C, D, or E, calculated from a previous kidney ultrasound or MRI performed within the last 12 months
  • Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus
  • Tolvaptan usage or plans to initiate tolvaptan
  • History of hospitalization or major surgery within the last 3 months
  • Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)
  • Pregnancy, lactation, or unwillingness to use adequate
  • Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism
  • History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder
  • Weight change of >5% in the past 3 months for any reason except post-partum weight loss
  • Inability to cooperate with or clinical for MRI including: severe claustrophobia, implants, devices, or non-removable body piercings
  • Presence or personal history of malignant neoplasm within 5 years prior to the day of screening
  • Personal or family history of medullary thyroid carcinoma, thyroid nodule, or multiple endocrine neoplasia type 2
  • Prior history of pancreatitis
  • Weight ≥450 lb
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Tirzepatide

    To minimize the risk of gastrointestinal adverse events, we will use a standard dose-escalation regimen for tirzepatide (placebo-matched), starting at 2.5 mg once weekly (OW) at randomization. After 4 weeks of treatment at 2.5 mg, the dose will be escalated to 5 mg OW, which will be maintained for another 4 weeks and then continued as the target dose for 10 months until the end of treatment. As with other nutrient stimulating hormone (NuSH) therapies, dose reductions and extensions of dose-escalation intervals will be permitted if participants experience unacceptable adverse events. The minimum tolerated dose required for continued study participation is 2.5 mg/week. All dose changes will be documented in the study records.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    To minimize the risk of gastrointestinal adverse events, we will use a standard dose-escalation regimen for tirzepatide (placebo-matched), starting at 2.5 mg once weekly (OW) at randomization. After 4 weeks of treatment at 2.5 mg, the dose will be escalated to 5 mg OW, which will be maintained for another 4 weeks and then continued as the target dose for 10 months until the end of treatment. As with other nutrient stimulating hormone (NuSH) therapies, dose reductions and extensions of dose-escalation intervals will be permitted if participants experience unacceptable adverse events. The minimum tolerated dose required for continued study participation is 2.5 mg/week. All dose changes will be documented in the study records.

    Other: Placebo

Interventions

  • Titrated to dose of 5 mg once weekly subcutaneous

    Also known as: Zepbound

  • OtherPlacebo

    Titrated to dose of 5 mg once weekly subcutaneous

06

What researchers measure

Primary outcomes

  1. Change in height-Adjusted Total kidney volume

    To assess kidney growth,height-adjusted total kidney volume will be measured by magnetic resonance imaging at baseline and 12 months to determine annual percent change.

    Time frame: Baseline, 12-months

Secondary outcomes

  1. Change in body weight

    Change in body weight over the 12-month period will be measured using a calibrated digital scale.

    Time frame: Baseline, 12-months

  2. Change in abdominal adiposity

    Abdominal adiposity (subcutaneous, visceral, and total) will be assessed by magnetic resonance imaging.

    Time frame: Baseline, 12-months

  3. Change in adiponectin (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  4. Change in leptin (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  5. Change in interleukin-6 (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  6. Change in tumor necrosis-factor-alpha (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  7. Change in high-sensitivity C-reactive protein (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  8. Change in 8-isoprostane (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  9. Change in copeptin (circulating)

    Venous blood samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  10. Change in HOMA-IR

    The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) will use fasting glucose and insulin to calcuate insulin sensitivity

    Time frame: Baseline, 6-months, 12-months

  11. Change in HOMA-β

    The Homeostatic Model Assessment of β-cell function (HOMA-β) will use fasting glucose and insulin to calcuate insulin secretion.

    Time frame: Baseline, 6-months, 12-months

  12. Change in 8-isoprostane (urinary)

    Sport urine samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  13. Change in copeptin (urinary)

    Sport urine samples will be analyzed for this mechanistic biomarker

    Time frame: Baseline, 6-months, 12-months

  14. Change in renal oxygen consumption

    Renal oxygen consumption will be assessed by a PET/CT scan using 11-C acetate in a sub-set of participants

    Time frame: Baseline, 12-months

  15. Change in gut microbiota

    16S rRNA gene sequencing will be used for taxonomic characterization of the gut microbiota in a subset of participants.

    Time frame: Baseline, 12-months

Other outcomes

  1. Change in renal blood flow

    Phase contrast magentic resonance imaging will be used to measure change in renal blood flow

    Time frame: Baseline, 12-months

  2. Safety (adverse events)

    Number of participants with treatment-related adverse events in each group as evaluated by the DSMB

    Time frame: 12 months

  3. Adherence

    Compliance will be assessed by cross-checking the following sources and comparing these to the expected use: (1) drug accountability information; (2) counting returned trial product, visual inspection of pens; and (3) discussion with participants.

    Time frame: 12 months

  4. Tolerability (dropout due to adverse events)

    Subject dropout due to treatment-emergent adverse events

    Time frame: 12 months

  5. Kidney Function Decline

    Estimated glomerular filtration rate trajectories will be compared between the active and placebo group as an exploratory endpoint to inform a subsequent phase III trial.

    Time frame: Baseline, 1 month, 3 months, 6-months, 12-months

  6. Change in dietary energy Intake

    Multiple pass 24-hr dietary recalls will be analyzed to evaluate self-reported energy intake

    Time frame: Baseline, 1 month, 6-months, 12-months

  7. Change in free-living physical activity

    Estimated energy expenditure (METs) over a 7-day period will be quantified using the ActiGraph wGT3X-BT activity monitor

    Time frame: Baseline, 12-months

  8. Change in resting energy experniture

    Resting energy expenditure will be assessed using indirect calorimetry.

    Time frame: Baseline, 12 months

  9. Change in percent body fat

    Percent body fat will be assessed via DEXA scan in a sub-set of participants.

    Time frame: Baseline, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data obtained through this study may be provided to qualified researchers with academic interest in ADPKD. Data shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. data use agreement) are prerequisites to the sharing of data with the requesting party.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data requests can be submitted starting 9 months after article publication and the data will be made accessible for up to 24 months. Extensions will be considered on a case-by-case basis.

Access criteria: Access to trial IPD can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 51 months after the start.

Of 17 phase 2 interventional studies under Polycystic Kidney, Autosomal Dominant, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Sep 3, 2024
StartActual
Mar 6, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jun 30, 2029
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06582875
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Mar 6, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
May 6, 2025

Study contacts

Kristen Nowak, PhD, MPH
Contact
Kristen.Nowak@cuanschutz.edu
3037244842
Diana George
Contact
Diana.George@cuanschutz.edu
303-724-1684

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion